Table 2.

CD276 related clinical trials.

Condition or disease	Status
Relapsed and refractory neuroblastoma (NB)	Recruiting
CD276 positive solid tumor	Recruiting
Advanced CD276 positive solid tumor	Recruiting
Relapsed / refractory Acute Myeloid Leukemia	Recruiting
Central nervous system locoregional adoptive therapy	Recruiting
Recurrent Glioblastoma / Refractory Glioblastoma	Recruiting
Recurrent Glioblastoma / Refractory Glioblastoma	Recruiting
Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor	Completed
Advanced Solid Tumor, Metastatic Castrate Resistant Prostate Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer	Recruiting
Melanoma, Head and Neck Cancer, Non-small Cell Lung Cancer, Urethelial Carcinoma	Active, not recruiting
Advanced Solid Tumors	Active, not recruiting
Melanoma, Non-small Cell Lung Cancer	Completed
Melanoma	Terminated
Prostate Cancer	Active, not recruiting
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer	Completed

MGD009: B7-H3 x CD3 DART protein, is also known as orlotamab.

MGC018: Anti-B7-H3 antibody drug conjugate.

MGA012: Anti-PD-1 antibody, is also known as INCMGA00012.

MGA271: is also known as enoblituzumab.